Skip to main content
Premium Trial:

Request an Annual Quote

Houston Investment Bank Closes $11M Life Science Fund

NEW YORK, Oct. 1 – Houston-based investment banking firm Sanders Morris Harris has closed its $11 million LifeSciences Opportunity Fund, which will look to invest in early- and middle-stage functional genomics and proteomics companies.

"Our first LifeSciences Fund is focused on investing in companies with technologies that have a high likelihood of playing a key role in commercializing new scientific discoveries arising from the recent historical developments in biomedical research such as the human genome project," James Gale, a managing director at the firm, said in a statement released Friday.

The fund, which will also look to invest in drug delivery and gene therapy technologies, is designed to give individual investors the chance to invest in emerging medical technology.

So far, the fund has made two investments. Sanders Morris Harris has over $3 billion under management. 


The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.